Today: 28 June 2026
Nike stock slides after-hours as tariff whiplash keeps pressure on NKE
24 February 2026
2 mins read

Nike stock slides after-hours as tariff whiplash keeps pressure on NKE

New York, Feb 23, 2026, 18:42 EST — After-hours

  • Nike shares slid roughly 3.5% Monday, with Wall Street retreating as tariff jitters resurfaced.
  • Jefferies points to Nike as a stock that could come out ahead if the fresh tariff policy winds up cutting rates compared to prior duties.
  • Investors are scrutinizing the timetable for tariffs, any carve-outs, and the timing of Nike’s next earnings report.

Nike shares slipped in after-hours trading Monday, part of a broader pullback as U.S. President Donald Trump’s unexpected global tariff plan reignited worries around trade policy.

The stock slipped roughly 3.5% to $63.09, setting up what could be its steepest single-day decline in over a week.

Tariffs hit straight at costs for brands that rely on imports, so it’s no surprise investors have dumped discretionary stocks as policy headlines shift. Monday’s selloff drew money into safe havens—traders sticking to a routine play when rules look uncertain.

Trump is rolling out fresh tariffs just days after the Supreme Court tossed out his previous emergency duties. The new move bumps the rate up from 10% to 15%, this time using Section 122 of the Trade Act of 1974—a tool for imposing short-term, broad tariffs. But plenty of details are still murky: no clarity yet on timing, possible carveouts, or if the rate hits all countries equally.

“We are giving up roughly half of Friday’s gain … reminding us that uncertainty remains high,” Mark Hackett, chief market strategist at Nationwide in Philadelphia, said. Reuters

Nike found itself caught up in the selloff, despite a few analysts saying the newest tariff move might not hit as hard as past rounds. In a note picked up by Reuters, Jefferies pointed to Best Buy, Ralph Lauren, and Nike as names that could actually come out ahead if tariffs come down from previous levels.

Even so, the tariff story isn’t going away for Nike, given its global sourcing footprint. Not long ago, the company flagged that altered tariffs might tack on roughly $1 billion in extra costs. It’s responded by moving some footwear production out of China to limit the U.S. market’s exposure, according to previous statements.

Policy turbulence hits a crowded sector—competition is fierce, quick price cuts follow if demand slips. When costs rise and companies can’t push them onto customers, margins get squeezed before revenue feels it.

One risk: tariffs could spread wider or drag on longer than traders are pricing in, leaving brands stuck deciding whether to eat the extra costs, push up prices, or try both. If consumer confidence takes a steeper dive, the pressure only builds for apparel and footwear stocks.

Looking to the week ahead, investors want specifics from the White House on when the new tariffs kick in and exactly how broad they’ll be. Retailers’ commentary around sourcing and pricing could also move things. As for Nike, the company hasn’t set its next earnings date yet, though most on Wall Street have circled March 19.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Ripple's Preliminary EU MiCA Approval Raises Questions on RLUSD and XRP Impact in Europe
    June 28, 2026, 12:06 PM EDT. Ripple received a preliminary Luxembourg crypto-asset service provider (CASP) license under the EU's Markets in Crypto-Assets (MiCA) framework, allowing it to offer regulated services across 30 EEA countries pending final conditions. Despite this regulatory milestone, investors remain cautious about the XRP token's value driver, as Ripple's license ownership does not directly translate to increased activity on the XRP Ledger (XRPL). While Ripple's regulated stablecoin RLUSD's supply declined over 30 days, XRPL stablecoin value grew by over 20%, challenging XRP's current $1.05 price near a $65.5 billion market cap. The EU's July 1, 2026, MiCA enforcement deadline heightens the license's strategic importance, but tangible XRP Ledger usage remains the critical question for investors assessing Ripple's European payments push.

Latest articles

MSFT rally set for Russell reshuffle as AI spending jitters hang over stock

MSFT rally set for Russell reshuffle as AI spending jitters hang over stock

28 June 2026
Microsoft (MSFT) surged 5.71% to $372.97 on record volume as FTSE Russell index changes moved the stock into both growth and value indexes, driving a “really massive trade” and “key liquidity day”; investors now face uncertainty over real demand versus index flows, with capex and AI spending weighing on future profitability.
Amazon (NASDAQ:AMZN) trades after Prime Day jump, AWS in focus as basket sizes shrink

Amazon (NASDAQ:AMZN) trades after Prime Day jump, AWS in focus as basket sizes shrink

28 June 2026
Amazon closed Friday at $232.69, up 2.5% on massive volume, but still down 4.8% from June 18; Prime Day U.S. sales jumped 9.3% to $26.4 billion as average order size fell 10.6%, while AWS will raise AI compute prices by about 20% in July, spotlighting investor focus on whether higher AWS pricing can offset soaring AI infrastructure costs.
Ripple MiCA Approval Moves RLUSD, XRP (CRYPTO:XRP) Not Focus, in Europe Payments Push

Ripple MiCA Approval Moves RLUSD, XRP (CRYPTO:XRP) Not Focus, in Europe Payments Push

28 June 2026
Ripple’s preliminary Luxembourg crypto license could open regulated EU payments, but XRP traded near $1.05—still 71% below its 2025 high—as investors await proof that RLUSD stablecoin flows drive real demand on the XRP Ledger, not just Ripple’s private platform; RLUSD supply fell 9% in 30 days while XRPL stablecoin value rose 20%.
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Previous Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus
Next Story

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus

Go toTop